Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07622888

Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients

This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and/or pelvic oncologic surgery with pre-existing malnutrition. The study describes the course of postoperative gastrointestinal dysfunction and evaluates whether real-world exposure to parenteral serotonin as part of routine postoperative care is associated with a higher proportion of patients whose gastrointestinal dysfunction regresses to LIFE score less than or equal to 1 by postoperative day 5 (plus or minus 1 day), compared with patients not exposed to serotonin.

All treatment decisions, including the use of parenteral serotonin, metoclopramide, neostigmine, nutritional support, and other postoperative management, are made solely by the treating physicians in accordance with routine clinical practice. The protocol does not assign, randomize, require, or restrict any drug treatment; it records real-world care, daily LIFE assessments during postoperative days 1 through 7, nutritional status measures, body composition where available, delirium screening, complications, length of stay, and mortality.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Disease-related malnutrition and sarcopenia are common in patients undergoing major abdominal or pelvic oncologic surgery and are associated with worse postoperative outcomes, including more complications, prolonged hospital stay, and increased mortality. Postoperative gastrointestinal dysfunction may further impair tolerance of enteral nutrition and delay recovery, especially in patients with baseline malnutrition.

In routine practice at the participating centers, postoperative gastrointestinal dysfunction or functional ileus may be managed with different pharmacologic approaches, including metoclopramide, neostigmine, and in some patients parenteral serotonin. The choice of therapy, dose, timing, and duration is determined entirely by the treating clinicians according to routine care, approved labeling, and local institutional practice; no treatment is assigned by the protocol.

This study prospectively enrolls approximately 120 adult patients with histologically or cytologically confirmed malignancy who are scheduled for major abdominal and/or pelvic oncologic surgery and have pre-existing malnutrition defined by NRS-2002 score at least 3 plus at least one phenotypic and one etiologic GLIM criterion. Participants are observed from the preoperative period through discharge or postoperative day 30, whichever occurs first.

Exposure cohorts are defined after inclusion according to whether parenteral serotonin was actually received during the early postoperative period as part of routine care. The primary endpoint is the proportion of participants with regression of gastrointestinal dysfunction to LIFE score less than or equal to 1 by postoperative day 5 within the postoperative day 4 to 6 assessment window.

Secondary outcomes include the trajectory of LIFE scores during postoperative days 1 to 7, time to restoration of gastrointestinal motility, time to achievement of at least 60 to 70 percent of calculated energy requirements via enteral nutrition, changes in nutritional status and body composition, delirium incidence and duration, postoperative complications graded by Clavien-Dindo, infectious complications, ICU and hospital length of stay, and mortality. The study is exploratory and is intended to characterize real-world postoperative trajectories and generate effect-size estimates for future studies rather than provide definitive proof of treatment superiority.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Histologically confirmed malignant tumor of the abdomen or pelvis with planned radical or cytoreductive surgery.
  • Baseline malnutrition defined as NRS2002 ≥ 3 and at least one phenotypic and one etiologic GLIM criterion.
  • Expected postoperative hospitalization ≥ 7 days.
  • Ability to undergo baseline cognitive and nutritional assessments (MoCA, NRS2002, GLIM, PG-SGA) prior to surgery.
  • Signed informed consent for participation and data collection.

Exclusion criteria

  • Severe decompensated hepatic or renal failure rendering surgery infeasible.
  • Documented preexisting severe cognitive impairment or dementia precluding valid postoperative cognitive/delirium assessment (e.g., MoCA < 18 or documented dementia).
  • Pregnancy or breastfeeding.
  • Participation in another interventional randomized clinical trial within the prior 30 days that could confound outcomes.
  • Inability to ensure postoperative follow-up or reliable data collection (planned transfer without access, loss of contact).

Treatment and study plan

Serotonin (e.g., serotonin adipinate)

Drug

Parenteral serotonin administered postoperatively per treating physician's discretion. Dose, duration, and co-administration with other prokinetics recorded.

Standard Prokinetic Therapy (excluding serotonin)

Drug

Use of metoclopramide, neostigmine, or other prokinetics per local practice, without serotonin.

Primary outcomes

  1. Proportion of participants with LIFE ≤ 1 by postoperative day 5 (POD5 ±1 day)

    Time frame: Postoperative day (POD) 5 ± 1 day (assessment window POD4-POD6)

    The proportion of participants whose gastrointestinal dysfunction regresses to a Lausanne Intestinal Failure Estimation (LIFE) score of ≤1 within the assessment window (POD4-POD6). LIFE is assessed once daily from POD1 through POD7 using routine clinical parameters.

Secondary outcomes

  1. Mean LIFE score from postoperative day 1 through postoperative day 7

    Time frame: Postoperative Days 1-7

    Average of daily LIFE scores measured once per day from POD1 to POD7. LIFE is a composite clinical score of gastrointestinal dysfunction. Mean LIFE over this period will be compared between serotonin exposed and non exposed cohorts to describe the trajectory of GI function.

  2. Time to restoration of gastrointestinal motility (first spontaneous bowel movement without clinical signs of significant GID)

    Time frame: From the date of surgery until the date of the first documented spontaneous bowel movement without clinically significant gastrointestinal dysfunction, assessed up to 30 days after surgery

    Number of days from surgery to the first documented spontaneous bowel movement without clinically significant ongoing gastrointestinal dysfunction (as judged by the treating team and LIFE score).

  3. Number of participants with at least one episode of delirium

    Time frame: From postoperative day 0 through postoperative day 10 after surgery or until hospital discharge, whichever occurs first.

    Proportion of participants with at least one positive delirium assessment using CAM ICU or ICDSC during ICU and ward stay.

  4. Number of delirium days

    Time frame: From postoperative day 0 through postoperative day 10 after surgery or until hospital discharge, whichever occurs first.

    Total number of calendar days with positive CAM-ICU or ICDSC assessments.

  5. Frequency of surgical complications (Clavien-Dindo, grade II-V)

    Time frame: Up to 30 days after surgery

    Proportion of participants who develop at least one postoperative complication of Clavien-Dindo grade II or higher; separate reporting of grade III-V complications.

  6. Frequency of infectious complications

    Time frame: Up to 30 days after surgery

    Proportion of participants with clinically diagnosed infectious complications (e.g., surgical site infection, pneumonia, intra abdominal abscess, sepsis) during the index hospitalization.

  7. ICU length of stay (days) and hospital length of stay (days)

    Time frame: Up to 30 days after surgery

    Number of days spent

    • in the ICU during the index postoperative stay
    • in the hospital for the index surgical admission.
  8. In-hospital mortality and 30-day mortality

    Time frame: Up to 30 days after surgery

    Proportion of participants who die

    • before discharge from the index hospitalization
    • within 30 days after surgery, based on hospital records and, where available, follow up information.
  9. Safety outcomes (CTCAE v6.0)

    Time frame: From the index hospitalization through 30 days after surgery

    Incidence of cardiovascular, hematologic, metabolic, and neuropsychiatric adverse events with emphasis on thrombotic events, serious arrhythmias, severe hypertensive reactions, and events compatible with serotonin syndrome

Other outcomes

  1. Change in body weight

    Time frame: From preoperative baseline to hospital discharge, assessed up to 30 days after surgery.

    Difference in body weight (kg) between baseline and discharge.

  2. Change in mid-upper arm circumference

    Time frame: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery

    Difference in mid upper arm circumference (cm) as a simple anthropometric marker of muscle mass.

  3. Change in fat-free mass (FFM)

    Time frame: Postoperative Day 6-10 or at hospital discharge, whichever occurs first

    Difference in FFM (kg) between baseline and postoperative day 6-10 (or discharge). For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.

  4. Change in skeletal muscle mass (SMM)

    Time frame: Postoperative Day 6-10

    Difference in SMM (kg) between baseline and postoperative day 6-10 (or discharge). For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.

  5. Change in skeletal muscle mass index (SMMI)

    Time frame: Postoperative Day 6-10 or at hospital discharge, whichever occurs first

    Difference in SMMI (kg/m²) between baseline and postoperative day 6-10 (or discharge). For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.

  6. Change in phase angle

    Time frame: Postoperative Day 6-10 or at hospital discharge, whichever occurs first

    Difference in phase angle (degrees) between baseline and postoperative day 6-10 (or discharge).For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.

  7. Change in Nutritional Risk Screening 2002 (NRS-2002) score from baseline to discharge

    Time frame: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery

    Difference in Nutritional Risk Screening 2002 (NRS-2002) total score between baseline (preoperative assessment) and the day of hospital discharge. The NRS-2002 total score ranges from 0 to 7; higher scores indicate greater nutritional risk. For reporting, present mean (SD) change and number (%) of participants with clinically relevant change (e.g., change ≥1 point).

  8. Change in Global Leadership Initiative on Malnutrition (GLIM) malnutrition severity category from baseline to discharge

    Time frame: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery

    Change in malnutrition severity category as defined by the Global Leadership Initiative on Malnutrition (GLIM) criteria between the preoperative baseline assessment and the day of hospital discharge. GLIM categories to be reported: No malnutrition, Moderate malnutrition, Severe malnutrition. For results reporting, present the number and proportion of participants in each GLIM category at baseline and at discharge, and the number and proportion of participants with a change in category (e.g., Moderate → Severe, Severe → Moderate, Any worsening, Any improvement).

  9. Change in Patient-Generated Subjective Global Assessment (PG-SGA) total score from baseline to discharge

    Time frame: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery

    Difference in Patient-Generated Subjective Global Assessment (PG-SGA) total score between baseline (preoperative assessment) and the day of hospital discharge. PG-SGA is a validated nutritional assessment instrument; higher total scores indicate worse nutritional status. For results reporting, present mean (SD) change and median (IQR), and report the number and proportion of participants with a clinically meaningful change (predefined in the SAP; e.g., change ≥2 points).

  10. Time to achievement of enteral nutrition ≥60-70% of calculated energy requirement

    Time frame: From initiation of postoperative nutritional support up to 30 days after surgery

    Number of days from initiation of postoperative nutritional support to the first day on which ≥60-70% of calculated daily energy requirements are delivered via the enteral route, sustained according to local practice. Calculated energy targets follow institutional nutritional protocols (typically ~25-30 kcal/kg/day).

Study contacts

Contact information is provided by the study sponsor or research team.

Igor Vrublevskii

CONTACT

[email protected]

+79672769997

Sponsors and collaborators

Lead sponsor

Arma Ltd.

Industry

Registry information

Official study title

Gastrointestinal Dysfunction, Nutritional Status, and Delirium in the Early Postoperative Period in Oncologic Surgical Patients With Pre-existing Malnutrition: A Prospective Two-Center Observational Cohort Study

Acronym: GIDNUT

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jun 3, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.